A role for TET2 in parathyroid carcinoma

Area of Science:

• Epigenetics
• Oncology
• Molecular Biology

Background:

• Primary hyperparathyroidism (pHPT) is rarely caused by parathyroid carcinoma (PC).
• TET proteins regulate 5-hydroxymethylcytosine (5hmC) levels, crucial in various cancers.
• Previous studies noted reduced 5hmC and altered TET1 expression in PCs.

Purpose of the Study:

• To investigate TET2 protein expression and its role in parathyroid carcinoma.
• To explore the mechanisms of TET2 deregulation, including epigenetic modifications.
• To assess TET2's function in cell growth and migration in PCs.

Main Methods:

• Immunohistochemistry and Western blotting to assess TET2 protein levels in PCs.
• TET2 knockdown in a parathyroid cell line (sHPT-1) to study its functional role.
• DNA sequencing of TET2 and quantitative bisulfite pyrosequencing of its promoter.
• Treatment of PC cells with a DNA methylation inhibitor (5-aza-2'-deoxycytidine).

Main Results:

• TET2 expression was very low or undetectable in all analyzed PCs.
• TET2 knockdown increased cell growth and migration in the parathyroid cell line.
• No inactivating mutations in TET2 were found; however, its promoter showed increased DNA methylation.
• Inhibition of DNA methylation increased TET2 gene expression in PC cells.

Conclusions:

• Epigenetic silencing of TET2 via DNA hypermethylation contributes to reduced 5hmC levels in PCs.
• TET2 plays a regulatory role in cell growth and migration, suggesting it acts as a tumor suppressor.
• TET2 deregulation is implicated in the pathogenesis of parathyroid carcinoma.